title: Effects of ACE inhibition on renal haemodynamics in essential hypertension and hypertension associated with chronic renal failure.
abstract: Angiotensin II has many actions in the kidney, including regulation and distribution of renal circulation and glomerular filtration, as well as effects on mesangial contraction and on the filtration coefficient. The reduction in circulating and intrarenal angiotensin II by angiotensin converting enzyme (ACE) inhibitors in essential hypertension is associated with a significant increase in renal blood flow and a decrease in filtration fraction, without changes in glomerular filtration rate. In addition, administration of ACE inhibitors can reduce proximal sodium reabsorption via changes in peritubular hydrostatic and oncotic forces resulting from the fall in postglomerular capillary resistance. In severe hypertension the state of the renal vasculature does not allow ACE inhibition to induce similar haemodynamic changes and, therefore, it cannot contribute to renal sodium handling that requires the recruitment of alternate mechanisms. In spite of this, ACE inhibitors may exert a protective effect on the renal function of patients with severe hypertension as well as in those with renal impairment, by lowering systemic and, probably, intraglomerular pressure, reducing proteinuria and slowing the progression of renal failure.
authors.affiliation: División Hipertensión, Academia Nacional de Medicina, Buenos Aires, Argentina.
authors.forename: R A
authors.initials: RA
authors.lastname: Sánchez
authors.forename: C A
authors.initials: CA
authors.lastname: Traballi
authors.forename: E J
authors.initials: EJ
authors.lastname: Marcó
authors.forename: B H
authors.initials: BH
authors.lastname: Gilbert
authors.forename: A J
authors.initials: AJ
authors.lastname: Ramírez
authors.forename: G
authors.initials: G
authors.lastname: Long
mesh_terms: D000293:Adolescent; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D017315:Cilazapril; D004656:Enalapril / Q000494:pharmacology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006977:Hypertension, Renal / Q000150:complications / Q000188:drug therapy; D007668:Kidney / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000494:pharmacology; D012079:Renal Circulation / Q000187:drug effects*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D011724:Pyridazines; D017315:Cilazapril; D004656:Enalapril